Les neurofilaments : un nouveau biomarqueur clé pour les cliniciens. Partie 2 : Neurofilaments, un intérêt au-delà des maladies neurodégénératives

Delaby, Constance;Bousiges, Olivier;Bouvier, Damien;Fillee, Catherine;Bedel, Aurélie;et.al.
(2022) Annales de Biologie Clinique — Vol. 80, n° 5, p. 441-450 (2022)

Files

2022_Delaby_Ann_Biol_Clin_441-450_Ab.pdf
  • Open Access
  • Adobe PDF
  • 412.88 KB
Download

Details

Authors
Show more
Abstract
(en) [Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases] Neurofilaments (Nf) are proteins selectively expressed in the cytoskeleton of neurons, and their increase is a marker of neuronal damage. The potential utility of neurofilament light chain (NfL) has recently increased considerably, well beyond neurodegenerative diseases, due to analytical advances that allow measurement of their concentrations (even low ones) in cerebrospinal fluid and blood. This article completes the first part, in which we presented the interest of NfL in the context of neurodegenerative diseases. Here we focus our review on other clinical contexts of neurological injury (such as traumatic brain injury, multiple sclerosis, stroke, and cancer) and present the potential value of NfL assay in the management of these patients, for both diagnosis and prognosis. We also discuss the added value of the NfL assay compared to other biomarkers commonly used in the described clinical situations.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Delaby, C., Bousiges, O., Bouvier, D., Fillee, C., Fourier, A., Mondésert, É., Nezry, N., Omar, S., Quadrio, I., Rucheton, B., Schraen-Maschke, S., Van Pesch, V., Vicca, S., Lehmann, S., & Bedel, A. (2022). Les neurofilaments : un nouveau biomarqueur clé pour les cliniciens. Partie 2 : Neurofilaments, un intérêt au-delà des maladies neurodégénératives. Annales de Biologie Clinique, 80(5), 441-450. https://doi.org/10.1684/abc.2022.1758 (Original work published 2022)